Next-generation sequencing holds promise for use in companion diagnostics, but will require a paradigm shift as well as changes to the regulatory landscape, according to a number of experts that presented at last week's American Association for Cancer Research meeting in San Diego.
Using NGS as CDx Will Require Paradigm Shift, Regulatory Changes, According to Experts at AACR
Premium
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.